The Barcelona Predictive Model of Clinically Significant Prostate Cancer
A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/6/1589 |
| _version_ | 1797472457318203392 |
|---|---|
| author | Juan Morote Angel Borque-Fernando Marina Triquell Anna Celma Lucas Regis Manel Escobar Richard Mast Inés M. de Torres María E. Semidey José M. Abascal Carles Sola Pol Servian Daniel Salvador Anna Santamaría Jacques Planas Luis M. Esteban Enrique Trilla |
| author_facet | Juan Morote Angel Borque-Fernando Marina Triquell Anna Celma Lucas Regis Manel Escobar Richard Mast Inés M. de Torres María E. Semidey José M. Abascal Carles Sola Pol Servian Daniel Salvador Anna Santamaría Jacques Planas Luis M. Esteban Enrique Trilla |
| author_sort | Juan Morote |
| collection | DOAJ |
| description | A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (<i>p</i> = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (<i>p</i> < 0.001), and from 0.743 to 0.858 in the external validation cohort (<i>p</i> < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories. |
| first_indexed | 2024-03-09T20:03:01Z |
| format | Article |
| id | doaj.art-8d6048fc058342f3848a874f8b953d0b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:03:01Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8d6048fc058342f3848a874f8b953d0b2023-11-24T00:41:09ZengMDPI AGCancers2072-66942022-03-01146158910.3390/cancers14061589The Barcelona Predictive Model of Clinically Significant Prostate CancerJuan Morote0Angel Borque-Fernando1Marina Triquell2Anna Celma3Lucas Regis4Manel Escobar5Richard Mast6Inés M. de Torres7María E. Semidey8José M. Abascal9Carles Sola10Pol Servian11Daniel Salvador12Anna Santamaría13Jacques Planas14Luis M. Esteban15Enrique Trilla16Department of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, 50009 Zaragoza, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Radiology, Vall d´Hebron Hospital, 08035 Barcelona, SpainDepartment of Radiology, Vall d´Hebron Hospital, 08035 Barcelona, SpainDepartment of Pathology, Vall d´Hebron Hospital, 08035 Barcelona, SpainDepartment of Pathology, Vall d´Hebron Hospital, 08035 Barcelona, SpainDepartment of Urology, Parc de Salut Mar, 08003 Barcelona, SpainDepartment of Urology, Parc de Salut Mar, 08003 Barcelona, SpainDepartment of Urology, Hospital Germans Trias I Pujol, 08916 Badalona, SpainDepartment of Urology, Hospital Germans Trias I Pujol, 08916 Badalona, SpainUrology Research Group, Vall d´ Hebron Research Institute, 08035 Barcelona, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainDepartment of Applied Mathematics, Escuela Universitaria Politécnica La Almunia, Universidad de Zaragoza, 50100 Zaragoza, SpainDepartment of Urology, Vall d’Hebron Hospital, 08035 Barcelona, SpainA new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (<i>p</i> = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (<i>p</i> < 0.001), and from 0.743 to 0.858 in the external validation cohort (<i>p</i> < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories.https://www.mdpi.com/2072-6694/14/6/1589clinically significant prostate cancermagnetic resonance imagingpredictive modelrisk calculator |
| spellingShingle | Juan Morote Angel Borque-Fernando Marina Triquell Anna Celma Lucas Regis Manel Escobar Richard Mast Inés M. de Torres María E. Semidey José M. Abascal Carles Sola Pol Servian Daniel Salvador Anna Santamaría Jacques Planas Luis M. Esteban Enrique Trilla The Barcelona Predictive Model of Clinically Significant Prostate Cancer Cancers clinically significant prostate cancer magnetic resonance imaging predictive model risk calculator |
| title | The Barcelona Predictive Model of Clinically Significant Prostate Cancer |
| title_full | The Barcelona Predictive Model of Clinically Significant Prostate Cancer |
| title_fullStr | The Barcelona Predictive Model of Clinically Significant Prostate Cancer |
| title_full_unstemmed | The Barcelona Predictive Model of Clinically Significant Prostate Cancer |
| title_short | The Barcelona Predictive Model of Clinically Significant Prostate Cancer |
| title_sort | barcelona predictive model of clinically significant prostate cancer |
| topic | clinically significant prostate cancer magnetic resonance imaging predictive model risk calculator |
| url | https://www.mdpi.com/2072-6694/14/6/1589 |
| work_keys_str_mv | AT juanmorote thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT angelborquefernando thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT marinatriquell thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT annacelma thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT lucasregis thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT manelescobar thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT richardmast thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT inesmdetorres thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT mariaesemidey thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT josemabascal thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT carlessola thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT polservian thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT danielsalvador thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT annasantamaria thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT jacquesplanas thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT luismesteban thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT enriquetrilla thebarcelonapredictivemodelofclinicallysignificantprostatecancer AT juanmorote barcelonapredictivemodelofclinicallysignificantprostatecancer AT angelborquefernando barcelonapredictivemodelofclinicallysignificantprostatecancer AT marinatriquell barcelonapredictivemodelofclinicallysignificantprostatecancer AT annacelma barcelonapredictivemodelofclinicallysignificantprostatecancer AT lucasregis barcelonapredictivemodelofclinicallysignificantprostatecancer AT manelescobar barcelonapredictivemodelofclinicallysignificantprostatecancer AT richardmast barcelonapredictivemodelofclinicallysignificantprostatecancer AT inesmdetorres barcelonapredictivemodelofclinicallysignificantprostatecancer AT mariaesemidey barcelonapredictivemodelofclinicallysignificantprostatecancer AT josemabascal barcelonapredictivemodelofclinicallysignificantprostatecancer AT carlessola barcelonapredictivemodelofclinicallysignificantprostatecancer AT polservian barcelonapredictivemodelofclinicallysignificantprostatecancer AT danielsalvador barcelonapredictivemodelofclinicallysignificantprostatecancer AT annasantamaria barcelonapredictivemodelofclinicallysignificantprostatecancer AT jacquesplanas barcelonapredictivemodelofclinicallysignificantprostatecancer AT luismesteban barcelonapredictivemodelofclinicallysignificantprostatecancer AT enriquetrilla barcelonapredictivemodelofclinicallysignificantprostatecancer |